(410b) Combining Reaction with Crystallization and a Size-Based Biocatalyst Separation for the Continuous Manufacturing of Amoxicillin
AIChE Annual Meeting
2022
2022 Annual Meeting
Pharmaceutical Discovery, Development and Manufacturing Forum
Continuous Processing in Drug Substance and Drug Product: Integrated Processes
Tuesday, November 15, 2022 - 3:51pm to 4:12pm
In this work, we combine the reaction and crystallization in the same mixed suspension mixed product removal (MSMPR) vessel to improve the selectivity and productivity of the system as well as intensify the overall process. Additionally, we operate the process in a continuous fashion, leading to increased productivity, decreased process footprint, and easier operation in comparison to a batch process. Biocatalyst retention within the reactor was achieved by immobilizing PGA on a solid support of a defined size range (300-425 μm), and withdrawal of the product slurry through a stainless-steel mesh filter of 300 μm, thereby achieving a size-based separation between product crystals and biocatalyst. As amoxicillin trihydrate crystals will grow much larger than 300 μm normally without intervention, an external wet-mill loop was employed to decrease their size below the mesh filter threshold. Additionally, crystallization of amoxicillin was observed to be rate limiting, so we investigated the use of a second MSMPR, operated in the absence of biocatalyst, to allow for its complete desupersaturation from solution. It was determined that a residence time of 1 hour was sufficient to desupersaturate amoxicillin and improve product yield by 10%. Lastly, while these process improvements led to a high productivity of 500 g/L/d, the conversion of the beta-lactam donating moiety, 6-aminopenicillinoic acid (6-APA), and the side-chain donor, 4-HPGME, were low at only 53% and 40%, respectively. To address this limitation, we were able to isolate both substrates separately via pH-swing crystallization at pH values of 4.0 and 8.0 for 6-APA and 4-HPGME, respectively, exploiting their solubilityâs opposite sensitivity to changes in pH. With the recovery and reuse of substrates, the overall conversion, defined as the fraction of the compound fed into the system which does not leave the system as waste, was improved to greater than 90% for both substrates.
- McDonald, M.A., A.S. Bommarius, and R.W. Rousseau, Enzymatic reactive crystallization for improving ampicillin synthesis. Chemical Engineering Science, 2017. 165: p. 81-88.
- Li, D., et al., Enhanced enzymatic production of cephalexin at high substrate concentration with in situ product removal by complexation. Food Technology and Biotechnology, 2008. 46: p. 461+.
- Aguirre, C., et al., Partition and substrate concentration effect in the enzymatic synthesis of cephalexin in aqueous two-phase systems. Process Biochemistry, 2010. 45(7): p. 1163-1167.
- Youshko, M.I., et al., Penicillin acylase-catalyzed synthesis of ampicillin in âaqueous solutionâprecipitateâ systems. High substrate concentration and supersaturation effect. Journal of Molecular Catalysis B: Enzymatic, 2000. 10(5): p. 509-515.